HNH
GALT icon

Hopwood Nicholas Hunter’s Galectin Therapeutics GALT Stock Holding History

Hopwood Nicholas Hunter’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Hold
69,295
– – 0.09% 107
2026
Q1 		$193K Hold
69,295
– – 0.06% 120
2025
Q4 		$288K Buy
+69,295
New +$365K 0.09% 109

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Hopwood Nicholas Hunter's GALT Position: Q2 2026 in Review

Hopwood Nicholas Hunter held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 69,295 shares worth $322K. The position accounts for 0.09% of the portfolio, ranked #107.

Hopwood Nicholas Hunter first reported a position in GALT in Q4 2025 and has held it in 3 quarters since. 97 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Hopwood Nicholas Hunter held 69,295 shares of Galectin Therapeutics worth $322K as of Q2 2026.
  • Hopwood Nicholas Hunter left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up 0.09% of Hopwood Nicholas Hunter's portfolio in Q2 2026, its #107 holding.
  • Hopwood Nicholas Hunter first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Hopwood Nicholas Hunter's 13F filing for Q2 2026, filed 14 Aug 2026.